Monthly Valuation Update, January Factsheet

RTW Biotech Opportunities Ltd

14 February 2024

 

LEI: 549300Q7EXQQH6KF7Z84

14 February 2024

RTW Biotech Opportunities Ltd

Monthly Valuation Update, January Factsheet

+2.5% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio") announces that the unaudited net asset value attributable to the ordinary shares of the Company (the "NAV") at the close of business on 31 January 2024 was US$407.1 million, or US$1.94 per ordinary share, +2.5% from the previous month.

The monthly factsheet is available on the Company's website:

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

It is important to note that this NAV and January Factsheet do not reflect the completion of the Arix Bioscience plc ("Arix") transaction (the "Transaction"), which closed after January month-end with the new RTW Bio shares being admitted to trading on 13 February 2024. It does, however, include the previously announced acquisition of a 25.5% stake in Arix for a total consideration of US$57.1 million (representing £1.37 per Arix share) as reported on 22 January. On 31 January, the Arix stake amounted to 13.7% of NAV and was held in the "other public" segment of the portfolio, and as such it is not shown on the January Factsheet, which only shows core positions.

The Company intends to publish, at the soonest opportunity, an indicative and estimated pro forma NAV and NAV per share as at the closing date of the Transaction, reflecting the completion of the Transaction and new share issuance.

For Further Information:

RTW Investments, LP	[phone]
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations	[e-mail]
Buchanan (PR & Communications Adviser)	[phone]
Charles Ryland
Henry Wilson
George Beale
Deutsche Numis (Joint Corporate Broker)	[phone]
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities (Joint Corporate Broker)	[phone]
Edward Peel
Alex Penney
Cadarn Capital (Distribution & IR Partner)	[phone]
David Harris
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director	[phone]
Morgan Stanley Fund Services USA LLC	[phone]

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

 

END